Slide 1: H1 2026 Results Presentation
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2026. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Agenda
Agenda I. Highlights II. Financial review III. Operational review & strategic initiatives IV. Outlook & summary CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of
Slide 4: I. Highlights
I. Highlights CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 4
Slide 5: Key figures and summary
Key figures and summary Summary In €m except otherwise stated H1 2025 H1 2026 +/- • Strong operational performance in H1 2026, with 29% EPS +2.7% organic1 growth vs H1 2025, and increased cash conversion as Eurofins Revenues 3,612 3,701 +2.5% reported moves beyond the peak of the five-year investmen
Slide 6: Delivery of significant margin expansion, with further drivers still to come
Delivery of significant margin expansion, with further drivers still to come + 130bps adjusted EBITDA margin expansion + 190bps reported EBITDA margin expansion • c.140bps of underlying leverage underpinned reported margin improvements +40bps 23.7% +c.140bps 23.3% • Drivers of reported EBITDA margin
Slide 7: Organic growth by activity, H1 2026
Organic growth by activity, H1 2026 Revenues (€m) Commentary Organic growth • Food & Feed Testing: In Europe, solid market momentum supported by mid-single-digit organic +2.7%1 3,701 growth across most geographies and end markets despite weather-related disruption in Q1. North 3,612 America saw stea
Slide 8: BioPharma organic growth remained soft, particularly in ancillary activities
BioPharma organic growth remained soft, particularly in ancillary activities – some improvement expected in H2 (€m) BioPharma revenues BioPharma Product Testing and others1 1,010 1,042 1,020 1,039 • Organic growth in North America remained solid, as Eurofins companies support customers investing 1,0
Slide 9: II. Financial review
II. Financial review CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9
Slide 10: H1 2026 results showing leverage throughout the P&L
H1 2026 results showing leverage throughout the P&L Half Year 2025 Half Year 2026 +/- Δ +/- Δ (€m) Adjusted Adjusted Adjusted Reported Reported Reported Results Results Results SDIs1 Results SDIs Results Results • Revenues increased y-o-y by 2.5% (mature) (mature) supported by organic growth of 2.7%
Slide 11: H1 2026 revenue bridge
H1 2026 revenue bridge (€m) Q1 2026: +2.5%1 Q2 2026: +3.0%1 H1 2026: +2.7%1 94 24 3,701 • Organic revenue growth of 2.7% 3,684 98 -21 • FX headwind of -2.9% in H1, as the 3,612 Euro strengthened against most -105 currencies compared to the prior year • M&A contribution of €22.5m to consolidated reve
Slide 12: Organic growth weighted towards Rest of World, margin expansion across all regions
Organic growth weighted towards Rest of World, margin expansion delivered across all regions Europe North America Rest of the World (€m) H1 2025 H1 2026 Δ H1 2025 H1 2026 Δ H1 2025 H1 2026 Δ 2.0% organic 2.0% organic 9.1% organic Revenues 1,855 1,961 1,371 1,334 386 406 5.7% reported -2.7% reported
Slide 13: Mature scope profitability rising further above Group objective
Mature scope profitability rising further above Group objective, non-mature scope headwind reduced Mature scope Non-mature scope Total (€m) H1 2025 H1 2026 Δ H1 2025 H1 2026 Δ H1 2025 H1 2026 Δ Revenues 3,361 3,462 251 240 3,612 3,701 Reported EBITDA 793 870 -20 -8 773 862 % of revenues 23.6% 25.1%
Slide 14: Improved profitability and cash conversion supported capital returns with stable leverage
Improved profitability and cash conversion supported capital returns with stable leverage • Strong increase in both Free Cash Flow to the H1 2025 H1 2026 Firm and cash conversion4 in H1 2026, including: Δ€m Δ% €m €m Reported EBITDA 773 862 +88 11.4% o Continued improvement in NWC intensity to 4.9% o
Slide 15: Multi-year trajectory of higher cash generation
Multi-year trajectory of higher cash generation, with improvement across major components Capex (€m) and capex as % of Sales NWC intensity 1 8.1% 7.4% 6.9% 5.7% 259 252 251 212 6.8% 6.3% 5.5% 4.9% H1 2023 H1 2024 H1 2025 H1 2026 H1 2023 H1 2024 H1 2025 H1 2026 Reported EBITDA (€m) and Reported Free
Slide 16: III. Operational review & strategic initiatives
III. Operational review & strategic initiatives CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 16
Slide 17: Agreement to divest Electrical & Electronic Testing
Agreement to divest Electrical & Electronic Testing demonstrates strategic focus, and value embedded in Eurofins portfolio Divestment of business within Consumer & Technology Products Testing • On 14 April 2026, Eurofins announced an agreement to divest Electrical and Electronic Testing business (“M
Slide 18: Agreement to acquire Element Materials Technology's Life Sciences Testing Services business
Agreement to acquire Element Materials Technology’s Life Sciences Testing Services business in North America Aligned with ongoing capital allocation focus on core testing for life capabilities • On 20 July 2026, Eurofins announced an agreement with Element Materials Technology to acquire its Life Sc
Slide 19: Broader M&A activity continues, with 17 acquisitions closed in H1 2026
Broader M&A activity continues, with 17 acquisitions closed in H1 2026 17 Transactions closed in H1 2026 (10 share deals and 7 asset deals) Aggregated revenue of H1 26 acquisitions in FY 2025: >€80m North America Europe Rest of the World 6 Transactions 10 Transactions 1 Transaction Acquired: Acquire
Slide 20: Expansion of global footprint, with step towards completion of European hub and spoke
Expansion of global footprint, with important step towards completion of European hub and spoke networks Key projects in H1 2026 Planned additions to owned sites in 2026-2028 Environment Testing Environment Testing Amersfoort, The Netherlands Jena, Germany 8,743 m² 1,107 m2 Mississauga, Canada Maast
Slide 21: We continue to lead in terms of innovation
We continue to lead in terms of innovation Some 2026 examples Hantavirus Testing Solutions for Emerging Public Health Threats1 Eurofins expanded its Hantavirus testing capabilities to support health authorities monitoring Hantavirus outbreaks, offering PCR, next-generation sequencing (NGS) and ELISA
Slide 22: IV. Outlook & summary
IV. Outlook & summary CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 22
Slide 23: Reiterating objectives for FY 2026, mid-term and FY 2027
Reiterating objectives for FY 2026, mid-term and FY 2027 • Eurofins targets mid-single-digit organic growth and potential revenues from acquisitions of €250m, consolidated at mid-year (€125m consolidated impact in 2026). Organic growth will depend on the speed of pick-up of business in certain ancil
Slide 24: Summary
Summary Eurofins is accumulating the operational benefits of its five-year investment plan, with profitability almost at the 2027 objectives with more than a year still to go, and cash generation continuing to strengthen as we move beyond peak investment levels Organic growth has not yet returned to
Slide 25: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 25
Slide 26: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2026]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 26
Slide 27: Investments in start-ups are contributing materially to growth, with losses declining
Investments in start-ups are contributing materially to growth, with losses declining Number of start-ups initiated annually peaked in 2022-23 Start-up investments complement M&A strategy: 50 50 + 18 BCPs +49 BCPs • When acquisitions are too expensive or unavailable • High growth markets often lack
Slide 28: Breakdown of revenue by Operating Segment
Breakdown of revenue by Operating Segment 2024 2025 2026 As % of total €m Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 H1 Sales 850 897 873 929 3,549 893 962 950 1,024 3,829 957 1,004 1,961 53% Europe Organic growth in the Core 5.1% 3.5% 4.9% 2.9% 1.6% 3.6% 5.0% 3.3% 1.6% 2.3% 2.0% Business1 Sales 628 683 66
Slide 29: Breakdown of revenue by Area of Activity
Breakdown of revenue by Area of Activity 2024 2025 2026 As % €m Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 Q2 H1 of total Sales 664 715 714 776 2,869 718 755 761 809 3,043 734 813 1,547 42% Life Organic growth in the Core 7.2% 6.7% 7.4% 5.1% 6.1% 7.2% 5.9% 6.1% 4.2% 5.3% 4.8% Business1 Sales 489 511 501 509 2
Slide 30: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items – include one-off costs from network expansion, integration and reorganisation, discontin